TWiV 1331: A drug for cervical cancer

A groundbreaking drug targeting the HPV-16 E6 oncoprotein has shown remarkable promise in restoring p53 function and suppressing tumor growth in preclinical models, offering a potential cure for cervical and other HPV-driven cancers. Unlike existing vaccines that prevent infection, this covalent inhibitor works by irreversibly binding to a cysteine residue in E6, disrupting its ability to degrade p53—a key tumor suppressor. In mouse models, the drug slowed tumor growth and induced apoptosis in cancer cells, with no effect on non-HPV cells. The study, led by researchers from Indiana University and Covina Therapeutics, demonstrates that the E6 oncoprotein is druggable, opening a new frontier in targeted cancer therapy. The discovery is especially significant given that HPV-16 causes half of all global cervical cancers. Meanwhile, the episode also covers the ongoing H5N1 outbreak in U.S. dairy cattle, where the virus spreads rapidly despite no evidence of transmission through milking equipment or milk, raising urgent questions about the true transmission route. The episode closes with reflections on space exploration, the ethics of private space ventures, and the surprising potential of vaccinating invertebrates like bees and shrimp using innate immune memory.